MedTrace Logo

Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study

NCT04080544 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2023-09-28

Study results available
· View outcomes & findings →

Summary

The investigators will conduct tau positron emission tomography (PET) scans on 125 adults using the radiopharmaceutical Flortaucipir F18 (\[18F\]AV-1451). This will allow the investigators to determine tau deposition across adults of different ages and assess the relationship of current tau burden to cognitive function and amyloid deposition collected over the previous 10-year interval.

Conditions

Interventions

DRUG

[18F]AV-1451

The subject will receive up to a target dose of 370 megabecquerel (MBq) as a single IV bolus of \[18F\]AV-1451.

PROCEDURE

Positron Emission Tomography

Approximately 80 minutes after injection subjects will be placed in the UTSW PET/CT scanner for a 20-minute brain scan.

Sponsors & Collaborators

  • Neil M Rofsky, MD, MHA

    lead OTHER

Principal Investigators

  • Denise Park, PhD · University of Texas at Dallas

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
38 Years
Max Age
96 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-15
Primary Completion
2022-06-30
Completion
2022-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04080544 on ClinicalTrials.gov